The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases
Figure 3
Box plots displays the comparison between GLYCOV (a, b) and CA125 (c, d) marker for early-stage serous EOC patients (FIGO stages I and II), patients with benign ovarian diseases and healthy controls. All values were transformed logarithmically to reduce the skewness in the distribution of the values. values were calculated using the non-parametric Kruskal-Wallis pairwise comparison. values lower than 0.05 are determined as statistically significant; , and are statistically significant at the given value.
